Interesting OSCR Put And Call Options For February 2026

Oscar Health (OSCR) is highlighted for two option strategies around the current price of $15.38: selling the $13.00 put (bid $0.55) would set an effective cost basis of $12.45 and is out‑of‑the‑money by ~15% with a 73% chance of expiring worthless, representing a 4.23% return (24.13% annualized). Alternatively, selling a covered call at the $18.00 strike (bid $1.00) would cap sale at $18.00, implying a 23.54% total return if called by Feb 2026 and has a 61% chance of expiring worthless, with the put implied vol at 96%, the call implied vol at 85% and trailing 12‑month volatility at 82%.

Analysis

Market structure: Option sellers and cash-rich income-seeking investors are the short‑term winners — selling the Feb 2026 $13 put nets $0.55 with a 73% modeled chance of expiring worthless, and covered‑call sellers at $18 can pocket $1 with a 61% chance of keeping premium. Small‑cap insurer equity holders (OSCR holders) face concentrated gamma and assignment risk; large incumbents (e.g., UNH) are mostly unaffected. The elevated IV (85–96% vs realized 82%) signals a seller’s market for premium and asymmetric risk pricing in OSCR specifically.

Risk assessment: Key tail risks include adverse regulatory action on insurance reimbursement or a Medicaid enrollee shock that could drop shares >30% (low probability, high impact). Short horizon (≈8–9 weeks to Feb 2026) is dominated by option expiration and IV movements; medium (months) by enrollment/earnings cadence; long (>1 year) by unit economics and MA market share. Hidden dependencies: MA/Medicaid mix, reinsurance coverage, and capital needs — a surprise earnings miss or reserve build could blow up short premium trades.

Trade implications: Direct plays — use cash‑secured puts at $13 (Feb 2026) sized 1–3% portfolio to acquire OSCR at $12.45 cost or capture ~4.2% yield on cash; if already long, sell $18 Feb calls to lock ~23.5% capped return. Volatility trade — sell calendar/vertical put spreads (sell $13 / buy $10) to monetize rich put IV while capping tail risk; avoid naked short puts >3% portfolio. Sector rotation: favor higher‑quality insurers (UNH) for defensive ballast and trim other small‑cap health insurers with similar IV skew.

Contrarian angles: The market understates regulatory tail risk — the 73%/61% odds assume stable fundamentals; if enrollment metrics or policy headlines shift, realized loss could exceed implied probabilities. The high IV premium vs realized volatility suggests options are slightly over‑priced, but tail risk is concentrated — mispricing exists for structured bullish entries (buy stock + sell calls or sell put spreads) while buying deep protective puts (e.g., $10 strike) remains cheap relative to potential drawdowns. Historical parallel: prior small‑insurer rallies collapsed on regulatory scrutiny, so cap position sizes and buy explicit tail protection.

Key Decisions for Investors

• Establish a 1–3% portfolio long in OSCR via selling cash‑secured Feb 2026 $13 puts at $0.55 (effective acquisition $12.45). Size so max notional ≤3% equity exposure; if assigned, immediately sell Feb 2026 $18 covered calls for $1 to target a 23.5% capped return.
• If unwilling to be assigned, implement a put‑spread: sell Feb 2026 $13 put and buy Feb 2026 $10 put to limit tail loss; target net credit ≥$0.25 and cap max loss at ≈$2.75 per share. Close or roll if IV falls >15 vol points or premium decays to <25% of initial credit.
• For volatility sellers, avoid naked puts >3% portfolio and instead sell a series of calendar or vertical put spreads to collect premium; allocate no more than 20% of total options sleeve to OSCR due to concentrated regulatory risk.
• Hedge downside tail risk by buying one‑quarter size Feb 2026 $10 puts for every four sold $13 puts (or equivalently buy portfolio protective puts) if OSCR position >2% portfolio; exit hedge if OSCR >$18 for two consecutive weeks.
• Reduce beta in healthcare/insurer basket by adding +2% long UNH (or similar high‑quality insurer) as defensive ballast and trim other small‑cap insurer exposures by 1–2% to limit correlation risk ahead of next earnings/regulatory windows (next 30–90 days).